首页 > 最新文献

Medical Decision Making最新文献

英文 中文
Eliciting Risk Perceptions: Does Conditional Question Wording Have a Downside? 激发风险意识:条件性问题措辞是否有缺点?
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-02-01 Epub Date: 2024-01-18 DOI: 10.1177/0272989X231223491
Jeremy D Strueder, Jane E Miller, Xianshen Yu, Paul D Windschitl

Background: To assess the impact of risk perceptions on prevention efforts or behavior change, best practices involve conditional risk measures, which ask people to estimate their risk contingent on a course of action (e.g., "if not vaccinated").

Purpose: To determine whether the use of conditional wording-and its drawing of attention to one specific contingency-has an important downside that could lead researchers to overestimate the true relationship between perceptions of risk and intended prevention behavior.

Methods: In an online experiment, US participants from Amazon's MTurk (N = 750) were presented with information about an unfamiliar fungal disease and then randomly assigned among 3 conditions. In all conditions, participants were asked to estimate their risk for the disease (i.e., subjective likelihood) and to decide whether they would get vaccinated. In 2 conditional-wording conditions (1 of which involved a delayed decision), participants were asked about their risk if they did not get vaccinated. For an unconditional/benchmark condition, this conditional was not explicitly stated but was still formally applicable because participants had not yet been informed that a vaccine was even available for this disease.

Results: When people gave risk estimates to a conditionally worded risk question after making a decision, the observed relationship between perceived risk and prevention decisions was inflated (relative to in the unconditional/benchmark condition).

Conclusions: The use of conditionals in risk questions can lead to overestimates of the impact of perceived risk on prevention decisions but not necessarily to a degree that should call for their omission.

Highlights: Conditional wording, which is commonly recommended for eliciting risk perceptions, has a potential downside.It can produce overestimates of the true relationship between perceived risk and prevention behavior, as established in the current work.Though concerning, the biasing effect of conditional wording was small-relative to the measurement benefits that conditioning usually provides-and should not deter researchers from conditioning risk perceptions.More research is needed to determine when the biasing impact of conditional wording is strongest.

背景:目的:确定有条件措辞的使用--它将人们的注意力吸引到一种特定的或然情况--是否会导致研究人员高估风险认知与预期预防行为之间的真实关系:在一项在线实验中,亚马逊 MTurk 的美国参与者(N = 750)被展示了一种陌生真菌疾病的相关信息,然后被随机分配到 3 个条件中。在所有条件下,参与者都被要求估计自己患上该疾病的风险(即主观可能性),并决定是否接种疫苗。在 2 个条件式条件中(其中 1 个条件涉及延迟决定),参与者被问及如果不接种疫苗的风险。在一个无条件/基准条件中,这个条件没有明确说明,但仍然正式适用,因为参与者还没有被告知这种疾病有疫苗可用:结果:当人们在做出决定后对有条件措辞的风险问题进行风险估计时,观察到的感知风险与预防决定之间的关系被夸大了(相对于无条件/基准条件):结论:在风险问题中使用条件措辞可能会导致过高估计感知风险对预防决策的影响,但其程度不一定会导致忽略条件措辞:尽管令人担忧,但条件措辞的偏差效应较小--相对于条件措辞通常提供的测量益处而言--不应该阻止研究人员对风险感知施加条件。
{"title":"Eliciting Risk Perceptions: Does Conditional Question Wording Have a Downside?","authors":"Jeremy D Strueder, Jane E Miller, Xianshen Yu, Paul D Windschitl","doi":"10.1177/0272989X231223491","DOIUrl":"10.1177/0272989X231223491","url":null,"abstract":"<p><strong>Background: </strong>To assess the impact of risk perceptions on prevention efforts or behavior change, best practices involve conditional risk measures, which ask people to estimate their risk contingent on a course of action (e.g., \"if not vaccinated\").</p><p><strong>Purpose: </strong>To determine whether the use of conditional wording-and its drawing of attention to one specific contingency-has an important downside that could lead researchers to overestimate the true relationship between perceptions of risk and intended prevention behavior.</p><p><strong>Methods: </strong>In an online experiment, US participants from Amazon's MTurk (<i>N</i> = 750) were presented with information about an unfamiliar fungal disease and then randomly assigned among 3 conditions. In all conditions, participants were asked to estimate their risk for the disease (i.e., subjective likelihood) and to decide whether they would get vaccinated. In 2 conditional-wording conditions (1 of which involved a delayed decision), participants were asked about their risk if they did not get vaccinated. For an unconditional/benchmark condition, this conditional was not explicitly stated but was still formally applicable because participants had not yet been informed that a vaccine was even available for this disease.</p><p><strong>Results: </strong>When people gave risk estimates to a conditionally worded risk question after making a decision, the observed relationship between perceived risk and prevention decisions was inflated (relative to in the unconditional/benchmark condition).</p><p><strong>Conclusions: </strong>The use of conditionals in risk questions can lead to overestimates of the impact of perceived risk on prevention decisions but not necessarily to a degree that should call for their omission.</p><p><strong>Highlights: </strong>Conditional wording, which is commonly recommended for eliciting risk perceptions, has a potential downside.It can produce overestimates of the true relationship between perceived risk and prevention behavior, as established in the current work.Though concerning, the biasing effect of conditional wording was small-relative to the measurement benefits that conditioning usually provides-and should not deter researchers from conditioning risk perceptions.More research is needed to determine when the biasing impact of conditional wording is strongest.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"141-151"},"PeriodicalIF":3.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139486681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bias-Adjusted Predictions of County-Level Vaccination Coverage from the COVID-19 Trends and Impact Survey. COVID-19 趋势和影响调查对县级疫苗接种覆盖率的偏差调整预测。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-02-01 Epub Date: 2023-12-30 DOI: 10.1177/0272989X231218024
Marissa B Reitsma, Sherri Rose, Alex Reinhart, Jeremy D Goldhaber-Fiebert, Joshua A Salomon

Background: The potential for selection bias in nonrepresentative, large-scale, low-cost survey data can limit their utility for population health measurement and public health decision making. We developed an approach to bias adjust county-level COVID-19 vaccination coverage predictions from the large-scale US COVID-19 Trends and Impact Survey.

Design: We developed a multistep regression framework to adjust for selection bias in predicted county-level vaccination coverage plateaus. Our approach included poststratification to the American Community Survey, adjusting for differences in observed covariates, and secondary normalization to an unbiased reference indicator. As a case study, we prospectively applied this framework to predict county-level long-run vaccination coverage among children ages 5 to 11 y. We evaluated our approach against an interim observed measure of 3-mo coverage for children ages 5 to 11 y and used long-term coverage estimates to monitor equity in the pace of vaccination scale up.

Results: Our predictions suggested a low ceiling on long-term national vaccination coverage (46%), detected substantial geographic heterogeneity (ranging from 11% to 91% across counties in the United States), and highlighted widespread disparities in the pace of scale up in the 3 mo following Emergency Use Authorization of COVID-19 vaccination for 5- to 11-y-olds.

Limitations: We relied on historical relationships between vaccination hesitancy and observed coverage, which may not capture rapid changes in the COVID-19 policy and epidemiologic landscape.

Conclusions: Our analysis demonstrates an approach to leverage differing strengths of multiple sources of information to produce estimates on the time scale and geographic scale necessary for proactive decision making.

Implications: Designing integrated health measurement systems that combine sources with different advantages across the spectrum of timeliness, spatial resolution, and representativeness can maximize the benefits of data collection relative to costs.

Highlights: The COVID-19 pandemic catalyzed massive survey data collection efforts that prioritized timeliness and sample size over population representativeness.The potential for selection bias in these large-scale, low-cost, nonrepresentative data has led to questions about their utility for population health measurement.We developed a multistep regression framework to bias adjust county-level vaccination coverage predictions from the largest public health survey conducted in the United States to date: the US COVID-19 Trends and Impact Survey.Our study demonstrates the value of leveraging differing strengths of multiple data sources to generate estimates on the time scale and geographic scale necessary for proactive public health decision making.

背景:非代表性、大规模、低成本调查数据中可能存在的选择偏差会限制其在人口健康测量和公共卫生决策中的应用。我们从大规模的美国 COVID-19 趋势和影响调查中开发了一种方法来对县级 COVID-19 疫苗接种覆盖率预测进行偏差调整:设计:我们开发了一个多步骤回归框架,以调整县级疫苗接种覆盖率高原预测中的选择偏差。我们的方法包括对美国社区调查进行后分层,调整观察到的协变量差异,以及对无偏参考指标进行二次归一化。作为一项案例研究,我们前瞻性地应用了这一框架来预测县级 5-11 岁儿童的长期疫苗接种覆盖率。我们根据对 5-11 岁儿童 3 个月覆盖率的中期观察结果对我们的方法进行了评估,并使用长期覆盖率估计值来监测疫苗接种规模扩大速度的公平性:结果:我们的预测表明全国长期疫苗接种覆盖率的上限较低(46%),发现了巨大的地域差异(美国各县的覆盖率从 11% 到 91% 不等),并强调了在 5 到 11 岁儿童接种 COVID-19 疫苗紧急使用授权后 3 个月内扩大接种规模的步伐存在广泛差异:局限性:我们依赖于疫苗接种犹豫与观察到的覆盖率之间的历史关系,这可能无法反映 COVID-19 政策和流行病学状况的快速变化:我们的分析展示了一种方法,可利用多种信息来源的不同优势,在主动决策所需的时间尺度和地理范围内进行估算:设计综合健康测量系统,将在及时性、空间分辨率和代表性等方面具有不同优势的信息源结合起来,可以最大限度地提高数据收集的成本效益:这些大规模、低成本、非代表性的数据可能存在选择偏差,导致人们对其在人口健康测量中的效用产生质疑。我们开发了一个多步骤回归框架,对美国迄今为止最大规模的公共卫生调查--美国 COVID-19 趋势和影响调查--中得出的县级疫苗接种覆盖率预测结果进行偏差调整。我们的研究表明,利用多种数据源的不同优势来生成时间尺度和地理尺度上的估计值,对于前瞻性的公共卫生决策是非常有价值的。
{"title":"Bias-Adjusted Predictions of County-Level Vaccination Coverage from the COVID-19 Trends and Impact Survey.","authors":"Marissa B Reitsma, Sherri Rose, Alex Reinhart, Jeremy D Goldhaber-Fiebert, Joshua A Salomon","doi":"10.1177/0272989X231218024","DOIUrl":"10.1177/0272989X231218024","url":null,"abstract":"<p><strong>Background: </strong>The potential for selection bias in nonrepresentative, large-scale, low-cost survey data can limit their utility for population health measurement and public health decision making. We developed an approach to bias adjust county-level COVID-19 vaccination coverage predictions from the large-scale US COVID-19 Trends and Impact Survey.</p><p><strong>Design: </strong>We developed a multistep regression framework to adjust for selection bias in predicted county-level vaccination coverage plateaus. Our approach included poststratification to the American Community Survey, adjusting for differences in observed covariates, and secondary normalization to an unbiased reference indicator. As a case study, we prospectively applied this framework to predict county-level long-run vaccination coverage among children ages 5 to 11 y. We evaluated our approach against an interim observed measure of 3-mo coverage for children ages 5 to 11 y and used long-term coverage estimates to monitor equity in the pace of vaccination scale up.</p><p><strong>Results: </strong>Our predictions suggested a low ceiling on long-term national vaccination coverage (46%), detected substantial geographic heterogeneity (ranging from 11% to 91% across counties in the United States), and highlighted widespread disparities in the pace of scale up in the 3 mo following Emergency Use Authorization of COVID-19 vaccination for 5- to 11-y-olds.</p><p><strong>Limitations: </strong>We relied on historical relationships between vaccination hesitancy and observed coverage, which may not capture rapid changes in the COVID-19 policy and epidemiologic landscape.</p><p><strong>Conclusions: </strong>Our analysis demonstrates an approach to leverage differing strengths of multiple sources of information to produce estimates on the time scale and geographic scale necessary for proactive decision making.</p><p><strong>Implications: </strong>Designing integrated health measurement systems that combine sources with different advantages across the spectrum of timeliness, spatial resolution, and representativeness can maximize the benefits of data collection relative to costs.</p><p><strong>Highlights: </strong>The COVID-19 pandemic catalyzed massive survey data collection efforts that prioritized timeliness and sample size over population representativeness.The potential for selection bias in these large-scale, low-cost, nonrepresentative data has led to questions about their utility for population health measurement.We developed a multistep regression framework to bias adjust county-level vaccination coverage predictions from the largest public health survey conducted in the United States to date: the US COVID-19 Trends and Impact Survey.Our study demonstrates the value of leveraging differing strengths of multiple data sources to generate estimates on the time scale and geographic scale necessary for proactive public health decision making.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"175-188"},"PeriodicalIF":3.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10865746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Testing Nonmonotonicity in Health Preferences. 测试健康偏好中的非单调性。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-01-01 Epub Date: 2023-11-10 DOI: 10.1177/0272989X231207814
Jose-Maria Abellan-Perpiñan, Jorge-Eduardo Martinez-Perez, Jose-Luis Pinto-Prades, Fernando-Ignacio Sanchez-Martinez
<p><strong>Objective: </strong>The main aim of this article is to test monotonicity in life duration. Previous findings suggest that, for poor health states, longer durations are preferred to shorter durations up to some threshold or maximum endurable time (MET), and shorter durations are preferred to longer ones after that threshold.</p><p><strong>Methods: </strong>Monotonicity in duration is tested through 2 ordinal tasks: choices and rankings. A convenience sample (<i>n</i> = 90) was recruited in a series of experimental sessions in which participants had to rank-order health episodes and to choose between them, presented in pairs. Health episodes result from the combination of 7 EQ-5D-3L health states and 5 durations. Monotonicity is tested comparing the percentage rate of participants whose preferences were monotonic with the percentage of participants with nonmonotonic preferences for each health state. In addition, to test the existence of preference reversals, we analyze the fraction of people who switch their preference from rankings to choices.</p><p><strong>Results: </strong>Monotonicity is frequently violated across the 7 EQ-5D health states. Preference patterns for individuals describe violations ranging from almost 49% with choices to about 71% with rankings. Analysis performed by separate states shows that the mean rates of violations with choices and ranking are about 22% and 34%, respectively. We also find new evidence of preference reversals and some evidence-though scarce-of transitivity violations in choices.</p><p><strong>Conclusions: </strong>Our results show that there is a medium range of health states for which preferences are nonmonotonic. These findings support previous evidence on MET preferences and introduce a new "choice-ranking" preference reversal. It seems that the use of 2 tasks with a similar response scale may make preference reversals less substantial, although it remains important and systematic.</p><p><strong>Highlights: </strong>Two procedures based on ordinal comparisons are used to elicit preferences: direct choices and rankings. Our study reports significant rates of nonmonotonic preferences (or maximum endurable time [MET]-type preferences) for different combinations of durations and EQ-5D health states.Analysis for separate health states shows that the mean rates of nonmonotonicity range from 22% (choices) to 34% (rankings), but within-subject analysis shows that nonmonotonicity is even higher, ranging from 49% (choices) to 71% (rankings). These violations challenge the validity of multiplicative QALY models.We find that the MET phenomenon may affect particularly those EQ-5D health states that are in the middle of the severity scale and not so much the extreme health states (i.e., very mild and very severe states).We find new evidence of preference reversals even using 2 procedures of a similar (ordinal) nature. Percentage rates of preference reversals range from 1.5% to 33%. We also find some (althou
目的:本文的主要目的是检验寿命的单调性。先前的研究结果表明,对于健康状况不佳的状态,在达到某个阈值或最大可承受时间(MET)之前,较长的持续时间比较短的持续时间更可取,并且在该阈值之后,较短的时间比较长的时间更可取。方法:通过两个顺序任务:选择和排名来测试持续时间的单调性。便利样本(n = 90)是在一系列实验中招募的,在这些实验中,参与者必须按照健康事件的顺序进行排序,并在它们之间进行选择,两人一组。健康发作由7种EQ-5D-3L健康状态和5种持续时间的组合引起。单调性是通过比较每个健康状态下偏好单调的参与者的百分比和非单调偏好的参与者的比例来测试的。此外,为了检验偏好逆转的存在,我们分析了将偏好从排名转换为选择的人的比例。结果:在7个EQ-5D健康州中,单调性经常受到侵犯。个人偏好模式描述的违规行为从近49%的选择到71%的排名不等。各州进行的分析显示,选择和排名的平均违规率分别约为22%和34%。我们还发现了偏好逆转的新证据,以及一些在选择中违反及物性的证据。结论:我们的研究结果表明,有一个中等范围的健康状态的偏好是非单调的。这些发现支持了先前关于MET偏好的证据,并引入了一种新的“选择排名”偏好逆转。似乎使用两个反应量表相似的任务可能会使偏好逆转变得不那么实质,尽管这仍然是重要和系统的。亮点:基于顺序比较的两个程序用于引出偏好:直接选择和排名。我们的研究报告了不同持续时间和EQ-5D健康状态组合的非单调偏好(或最大可承受时间[MET]型偏好)的显著比率。对不同健康状态的分析显示,非单调性的平均发生率在22%(选择)到34%(排名)之间,但受试者内部分析显示,不单调性甚至更高,在49%(选择)和71%(排名)范围内。这些违规行为挑战了乘法QALY模型的有效性。我们发现,MET现象可能特别影响严重程度中等的EQ-5D健康状态,而不是极端健康状态(即非常轻微和非常严重的状态)。我们发现,即使使用两种类似(有序)性质的程序,偏好逆转的新证据也会出现。优惠逆转的百分比从1.5%到33%不等。我们还发现了一些(尽管很少)违反及物性的证据。
{"title":"Testing Nonmonotonicity in Health Preferences.","authors":"Jose-Maria Abellan-Perpiñan, Jorge-Eduardo Martinez-Perez, Jose-Luis Pinto-Prades, Fernando-Ignacio Sanchez-Martinez","doi":"10.1177/0272989X231207814","DOIUrl":"10.1177/0272989X231207814","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;The main aim of this article is to test monotonicity in life duration. Previous findings suggest that, for poor health states, longer durations are preferred to shorter durations up to some threshold or maximum endurable time (MET), and shorter durations are preferred to longer ones after that threshold.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Monotonicity in duration is tested through 2 ordinal tasks: choices and rankings. A convenience sample (&lt;i&gt;n&lt;/i&gt; = 90) was recruited in a series of experimental sessions in which participants had to rank-order health episodes and to choose between them, presented in pairs. Health episodes result from the combination of 7 EQ-5D-3L health states and 5 durations. Monotonicity is tested comparing the percentage rate of participants whose preferences were monotonic with the percentage of participants with nonmonotonic preferences for each health state. In addition, to test the existence of preference reversals, we analyze the fraction of people who switch their preference from rankings to choices.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Monotonicity is frequently violated across the 7 EQ-5D health states. Preference patterns for individuals describe violations ranging from almost 49% with choices to about 71% with rankings. Analysis performed by separate states shows that the mean rates of violations with choices and ranking are about 22% and 34%, respectively. We also find new evidence of preference reversals and some evidence-though scarce-of transitivity violations in choices.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Our results show that there is a medium range of health states for which preferences are nonmonotonic. These findings support previous evidence on MET preferences and introduce a new \"choice-ranking\" preference reversal. It seems that the use of 2 tasks with a similar response scale may make preference reversals less substantial, although it remains important and systematic.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;Two procedures based on ordinal comparisons are used to elicit preferences: direct choices and rankings. Our study reports significant rates of nonmonotonic preferences (or maximum endurable time [MET]-type preferences) for different combinations of durations and EQ-5D health states.Analysis for separate health states shows that the mean rates of nonmonotonicity range from 22% (choices) to 34% (rankings), but within-subject analysis shows that nonmonotonicity is even higher, ranging from 49% (choices) to 71% (rankings). These violations challenge the validity of multiplicative QALY models.We find that the MET phenomenon may affect particularly those EQ-5D health states that are in the middle of the severity scale and not so much the extreme health states (i.e., very mild and very severe states).We find new evidence of preference reversals even using 2 procedures of a similar (ordinal) nature. Percentage rates of preference reversals range from 1.5% to 33%. We also find some (althou","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"42-52"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72015966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Through the Eyes of Patients: The Effect of Training General Practitioners and Nurses on Perceived Shared Decision-Making Support. 从病人的角度看:全科医生和护士培训对感知共同决策支持的影响。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-01-01 Epub Date: 2023-10-24 DOI: 10.1177/0272989X231203693
Danique W Bos-van den Hoek, Ellen M A Smets, Rania Ali, Dorien Tange, Hanneke W M van Laarhoven, Inge Henselmans

Purpose: To examine the effects of training general practitioners and nurses in shared decision-making (SDM) support as perceived by cancer patients and survivors.

Design: An innovative, experimental design was adopted that included analogue patients (APs), that is, people who have or have had cancer and who imagine themselves in the position of the actor-patient presented in a video. Each AP assessed a video-recorded simulated consultation of a health care professional (HCP) conducted before or after an SDM support training program. The primary outcome was the APs' perceived SDM support with 13 self-developed items reflecting the perceived patient benefit of SDM support as well as the perceived HCP support behavior. Secondary outcomes included an overall rating of SDM support, AP-reported extent of SDM (CollaboRATE), satisfaction with the communication (Patient Satisfaction Questionnaire), conversation appreciation and helpfulness, as well as decision-making satisfaction and confidence (visual analog scale, 0-100). In addition, patient and HCP characteristics associated with AP-perceived SDM support were examined.

Results: APs (n = 131) did not significantly differentiate trained from untrained HCPs in their perceptions of SDM support nor in secondary outcomes. Agreement between APs' perceptions was poor. The higher the perceived comparability of the consultation with APs' previous personal experiences, the higher their rating of SDM support.

Limitations: We used a nonvalidated primary outcome and an innovative study design that should be tested in future work.

Conclusions: Despite the limitations of the study design, the training seemed to not affect cancer patients' and survivors' perceived SDM support.

Implications: The clinical relevance of the training on SDM support needs to be established. The variation in APs' assessments suggests patients differ in their perception of SDM support, stressing the importance of patient-tailored SDM support.

Highlights: Cancer patients and survivors did not significantly differentiate trained from untrained HCPs when evaluating SDM support, and agreement between their perceptions was poor.The clinical relevance of training GPs and nurses in SDM support needs to be established.Patient-tailored SDM support may be recommended, given the variation in APs' assessments and their possible diverging perceptions of SDM support.This innovative study design (having patients watch and assess videos of simulated consultations made in the context of training evaluation) needs to be further developed.

目的:研究癌症患者和幸存者对全科医生和护士进行共享决策(SDM)支持培训的效果。设计:采用了一种创新的实验设计,其中包括模拟患者(AP),即患有或曾经患有癌症的人,他们想象自己处于视频中出现的演员-患者的位置。每个AP评估了在SDM支持培训计划之前或之后对医疗保健专业人员(HCP)进行的视频模拟咨询。主要结果是AP感知到的SDM支持,其中13个项目反映了感知到的患者SDM支持的益处以及感知到的HCP支持行为。次要结果包括SDM支持的总体评分、AP报告的SDM程度(CollaboRATE)、对沟通的满意度(患者满意度问卷)、谈话欣赏和乐于助人,以及决策满意度和信心(视觉模拟量表,0-100)。此外,还检查了与AP感知的SDM支持相关的患者和HCP特征。结果:AP(n = 131)在对SDM支持的感知和次要结果方面都没有显著区分受过训练的HCP和未受过训练的DHCP。受影响者的认知一致性较差。咨询与AP以前的个人经历的可比性越高,他们对SDM支持的评分就越高。局限性:我们使用了一个未经验证的主要结果和一个创新的研究设计,应该在未来的工作中进行测试。结论:尽管研究设计存在局限性,但训练似乎不会影响癌症患者和幸存者对SDM支持的感知。影响:需要确定SDM支持培训的临床相关性。AP评估的差异表明,患者对SDM支持的感知不同,强调了患者量身定制的SDM支持的重要性。要点:癌症患者和幸存者在评估SDM支持时,没有显著区分受过训练的HCP和未经训练的HCPs,他们的认知一致性较差。需要确定在SDM支持方面培训全科医生和护士的临床相关性。考虑到AP评估的差异以及他们对SDM支持可能存在的不同看法,可以建议患者定制SDM支持。这种创新的研究设计(让患者观看和评估在培训评估背景下制作的模拟会诊视频)需要进一步发展。
{"title":"Through the Eyes of Patients: The Effect of Training General Practitioners and Nurses on Perceived Shared Decision-Making Support.","authors":"Danique W Bos-van den Hoek, Ellen M A Smets, Rania Ali, Dorien Tange, Hanneke W M van Laarhoven, Inge Henselmans","doi":"10.1177/0272989X231203693","DOIUrl":"10.1177/0272989X231203693","url":null,"abstract":"<p><strong>Purpose: </strong>To examine the effects of training general practitioners and nurses in shared decision-making (SDM) support as perceived by cancer patients and survivors.</p><p><strong>Design: </strong>An innovative, experimental design was adopted that included analogue patients (APs), that is, people who have or have had cancer and who imagine themselves in the position of the actor-patient presented in a video. Each AP assessed a video-recorded simulated consultation of a health care professional (HCP) conducted before or after an SDM support training program. The primary outcome was the APs' perceived SDM support with 13 self-developed items reflecting the perceived patient benefit of SDM support as well as the perceived HCP support behavior. Secondary outcomes included an overall rating of SDM support, AP-reported extent of SDM (CollaboRATE), satisfaction with the communication (Patient Satisfaction Questionnaire), conversation appreciation and helpfulness, as well as decision-making satisfaction and confidence (visual analog scale, 0-100). In addition, patient and HCP characteristics associated with AP-perceived SDM support were examined.</p><p><strong>Results: </strong>APs (<i>n</i> = 131) did not significantly differentiate trained from untrained HCPs in their perceptions of SDM support nor in secondary outcomes. Agreement between APs' perceptions was poor. The higher the perceived comparability of the consultation with APs' previous personal experiences, the higher their rating of SDM support.</p><p><strong>Limitations: </strong>We used a nonvalidated primary outcome and an innovative study design that should be tested in future work.</p><p><strong>Conclusions: </strong>Despite the limitations of the study design, the training seemed to not affect cancer patients' and survivors' perceived SDM support.</p><p><strong>Implications: </strong>The clinical relevance of the training on SDM support needs to be established. The variation in APs' assessments suggests patients differ in their perception of SDM support, stressing the importance of patient-tailored SDM support.</p><p><strong>Highlights: </strong>Cancer patients and survivors did not significantly differentiate trained from untrained HCPs when evaluating SDM support, and agreement between their perceptions was poor.The clinical relevance of training GPs and nurses in SDM support needs to be established.Patient-tailored SDM support may be recommended, given the variation in APs' assessments and their possible diverging perceptions of SDM support.This innovative study design (having patients watch and assess videos of simulated consultations made in the context of training evaluation) needs to be further developed.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"76-88"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10714703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimating a Preference-Based Value Set for the Mental Health Quality of Life Questionnaire (MHQoL). 心理健康生活质量问卷(MHQoL)基于偏好的值集估计。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-01-01 Epub Date: 2023-11-19 DOI: 10.1177/0272989X231208645
Frédérique C W van Krugten, Marcel F Jonker, Sebastian F W Himmler, Leona Hakkaart-van Roijen, Werner B F Brouwer

Background: Health economic evaluations using common health-related quality of life measures may fall short in adequately measuring and valuing the benefits of mental health care interventions. The Mental Health Quality of Life questionnaire (MHQoL) is a standardized, self-administered mental health-related quality of life instrument covering 7 dimensions known to be relevant across and valued highly by people with mental health problems. The aim of this study was to derive a Dutch value set for the MHQoL to facilitate its use in cost-utility analyses.

Methods: The value set was estimated using a discrete choice experiment (DCE) with duration that accommodated nonlinear time preferences. The DCE was embedded in a web-based self-complete survey and administered to a representative sample (N = 1,308) of the Dutch adult population. The matched pairwise choice tasks were created using a Bayesian heterogeneous D-efficient design. The overall DCE design comprised 10 different subdesigns, with each subdesign containing 15 matched pairwise choice tasks. Each participant was asked to complete 1 of the subdesigns to which they were randomly assigned.

Results: The obtained coefficients indicated that "physical health,""mood," and "relationships" were the most important dimensions. All coefficients were in the expected direction and reflected the monotonic structure of the MHQoL, except for level 2 of the dimension "future." The predicted values for the MHQoL ranged from -0.741 for the worst state to 1 for the best state.

Conclusions: This study derived a Dutch value set for the recently introduced MHQoL. This value set allows for the generation of an index value for all MHQoL states on a QALY scale and may hence be used in Dutch cost-utility analyses of mental healthcare interventions.

Highlights: A discrete choice experiment was used to derive a Dutch value set for the MHQoL.This allows the use of the MHQoL in Dutch cost-utility analyses.The dimensions physical health, mood, and relationships were the most important.The utility values range from -0.741 for the worst state to 1 for the best state.

背景:使用常见的与健康有关的生活质量指标进行健康经济评估,可能无法充分衡量和评价精神卫生保健干预措施的益处。心理健康生活质量问卷(MHQoL)是一种标准化的、自我管理的心理健康相关生活质量工具,涵盖7个维度,这些维度已知与心理健康问题相关,并受到心理健康问题患者的高度重视。本研究的目的是推导出MHQoL的荷兰值集,以促进其在成本效用分析中的使用。方法:使用离散选择实验(DCE)估计值集,该实验具有适应非线性时间偏好的持续时间。DCE嵌入在一个基于网络的自我完成调查中,并对荷兰成年人口的代表性样本(N = 1,308)进行了管理。配对选择任务采用贝叶斯异构d效率设计。整个DCE设计包括10个不同的子设计,每个子设计包含15个匹配的两两选择任务。每个参与者被要求完成他们随机分配的一个子设计。结果:得到的系数表明,“身体健康”、“情绪”和“关系”是最重要的维度。除第二级维度“未来”外,所有系数均在预期方向,反映了MHQoL的单调结构。MHQoL的预测值从最差状态的-0.741到最佳状态的1不等。结论:本研究得出了最近引入的MHQoL的荷兰值集。该值集允许在质量质量量表上为所有MHQoL州生成指标值,因此可用于荷兰精神保健干预措施的成本效用分析。重点:一个离散选择实验被用来推导MHQoL的荷兰值集。这允许在荷兰成本效用分析中使用MHQoL。身体健康、情绪和人际关系是最重要的。效用值的范围从-0.741(最差状态)到1(最佳状态)。
{"title":"Estimating a Preference-Based Value Set for the Mental Health Quality of Life Questionnaire (MHQoL).","authors":"Frédérique C W van Krugten, Marcel F Jonker, Sebastian F W Himmler, Leona Hakkaart-van Roijen, Werner B F Brouwer","doi":"10.1177/0272989X231208645","DOIUrl":"10.1177/0272989X231208645","url":null,"abstract":"<p><strong>Background: </strong>Health economic evaluations using common health-related quality of life measures may fall short in adequately measuring and valuing the benefits of mental health care interventions. The Mental Health Quality of Life questionnaire (MHQoL) is a standardized, self-administered mental health-related quality of life instrument covering 7 dimensions known to be relevant across and valued highly by people with mental health problems. The aim of this study was to derive a Dutch value set for the MHQoL to facilitate its use in cost-utility analyses.</p><p><strong>Methods: </strong>The value set was estimated using a discrete choice experiment (DCE) with duration that accommodated nonlinear time preferences. The DCE was embedded in a web-based self-complete survey and administered to a representative sample (<i>N</i> = 1,308) of the Dutch adult population. The matched pairwise choice tasks were created using a Bayesian heterogeneous D-efficient design. The overall DCE design comprised 10 different subdesigns, with each subdesign containing 15 matched pairwise choice tasks. Each participant was asked to complete 1 of the subdesigns to which they were randomly assigned.</p><p><strong>Results: </strong>The obtained coefficients indicated that \"physical health,\"\"mood,\" and \"relationships\" were the most important dimensions. All coefficients were in the expected direction and reflected the monotonic structure of the MHQoL, except for level 2 of the dimension \"future.\" The predicted values for the MHQoL ranged from -0.741 for the worst state to 1 for the best state.</p><p><strong>Conclusions: </strong>This study derived a Dutch value set for the recently introduced MHQoL. This value set allows for the generation of an index value for all MHQoL states on a QALY scale and may hence be used in Dutch cost-utility analyses of mental healthcare interventions.</p><p><strong>Highlights: </strong>A discrete choice experiment was used to derive a Dutch value set for the MHQoL.This allows the use of the MHQoL in Dutch cost-utility analyses.The dimensions physical health, mood, and relationships were the most important.The utility values range from -0.741 for the worst state to 1 for the best state.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"64-75"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10714713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138048310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential Adverse Outcomes of Shared Decision Making about Palliative Cancer Treatment: A Secondary Analysis of a Randomized Trial. 关于姑息性癌症治疗的共同决策的潜在不良后果:一项随机试验的二次分析。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-01-01 Epub Date: 2023-11-12 DOI: 10.1177/0272989X231208448
Loïs F van de Water, Danique W Bos-van den Hoek, Steven C Kuijper, Hanneke W M van Laarhoven, Geert-Jan Creemers, Serge E Dohmen, Helle-Brit Fiebrich, Petronella B Ottevanger, Dirkje W Sommeijer, Filip Y F de Vos, Ellen M A Smets, Inge Henselmans

Background: While shared decision making (SDM) is advocated for ethical reasons and beneficial outcomes, SDM might also negatively affect patients with incurable cancer. The current study explored whether SDM, and an oncologist training in SDM, are associated with adverse outcomes (i.e., patient anxiety, tension, helplessness/hopelessness, decisional uncertainty, and reduced fighting spirit).

Design: A secondary analysis of a randomized clinical trial investigating the effects of SDM interventions in the context of advanced cancer. The relations between observed SDM (OPTION12), specific SDM elements (4SDM), oncologist SDM training, and adverse outcomes were analyzed. We modeled adverse outcomes as a multivariate phenomenon, followed by univariate regressions if significant.

Results: In total, 194 patients consulted by 31 oncologists were included. In a multivariate analysis, observed SDM and adverse outcomes were significantly related. More specifically, more observed SDM in the consultation was related to patients reporting more tension (P = 0.002) and more decisional uncertainty (P = 0.004) at 1 wk after the consultation. The SDM element "informing about the options" was especially found to be related to adverse outcomes, specifically to more helplessness/hopelessness (P = 0.002) and more tension (P = 0.016) at 1 wk after the consultation. Whether the patient consulted an oncologist who had received SDM training or not was not significantly related to adverse outcomes. No relations with long-term adverse outcomes were found.

Conclusions: It is important for oncologists to realize that for some patients, SDM may temporarily be associated with negative emotions. Further research is needed to untangle which, when, and how adverse outcomes might occur and whether and how burden may be minimized for patients.

Highlights: Observed shared decision making was related to more tension and uncertainty postconsultation in advanced cancer patientsHowever, training oncologists in SDM did not affect adverse outcomes.Further research is needed to untangle which, when, and how adverse outcomes might occur and how burden may be minimized.

背景:虽然出于伦理原因和有益的结果,共同决策(SDM)被提倡,但SDM也可能对无法治愈的癌症患者产生负面影响。本研究探讨SDM和接受SDM培训的肿瘤学家是否与不良结果(即患者焦虑、紧张、无助/绝望、决策不确定性和斗志下降)有关。设计:对一项随机临床试验进行二次分析,研究SDM干预对晚期癌症的影响。分析观察到的SDM (OPTION12)、特定SDM元素(4SDM)、肿瘤学家SDM培训与不良结局之间的关系。我们将不良结果建模为多变量现象,如果显著,则进行单变量回归。结果:共纳入31位肿瘤学家咨询的194例患者。在多变量分析中,观察到的SDM与不良结局显著相关。更具体地说,在会诊中观察到更多的SDM与患者在会诊后1周报告更多的紧张(P = 0.002)和更多的决策不确定性(P = 0.004)有关。SDM元素“告知选择”被特别发现与不良结果有关,特别是在咨询后1周,更多的无助/绝望(P = 0.002)和更多的紧张(P = 0.016)。患者是否咨询了接受过SDM培训的肿瘤学家与不良结果无显著相关。没有发现与长期不良结果的关系。结论:肿瘤学家必须认识到,对于一些患者来说,SDM可能暂时与负面情绪相关。需要进一步的研究来弄清哪些、何时以及如何发生不良后果,以及是否以及如何将患者的负担降至最低。重点:观察到的共同决策与晚期癌症患者会诊后更多的紧张和不确定性有关。然而,对肿瘤学家进行SDM培训并没有影响不良结果。需要进一步的研究来弄清哪些、何时以及如何发生不良后果,以及如何将负担降至最低。
{"title":"Potential Adverse Outcomes of Shared Decision Making about Palliative Cancer Treatment: A Secondary Analysis of a Randomized Trial.","authors":"Loïs F van de Water, Danique W Bos-van den Hoek, Steven C Kuijper, Hanneke W M van Laarhoven, Geert-Jan Creemers, Serge E Dohmen, Helle-Brit Fiebrich, Petronella B Ottevanger, Dirkje W Sommeijer, Filip Y F de Vos, Ellen M A Smets, Inge Henselmans","doi":"10.1177/0272989X231208448","DOIUrl":"10.1177/0272989X231208448","url":null,"abstract":"<p><strong>Background: </strong>While shared decision making (SDM) is advocated for ethical reasons and beneficial outcomes, SDM might also negatively affect patients with incurable cancer. The current study explored whether SDM, and an oncologist training in SDM, are associated with adverse outcomes (i.e., patient anxiety, tension, helplessness/hopelessness, decisional uncertainty, and reduced fighting spirit).</p><p><strong>Design: </strong>A secondary analysis of a randomized clinical trial investigating the effects of SDM interventions in the context of advanced cancer. The relations between observed SDM (OPTION12), specific SDM elements (4SDM), oncologist SDM training, and adverse outcomes were analyzed. We modeled adverse outcomes as a multivariate phenomenon, followed by univariate regressions if significant.</p><p><strong>Results: </strong>In total, 194 patients consulted by 31 oncologists were included. In a multivariate analysis, observed SDM and adverse outcomes were significantly related. More specifically, more observed SDM in the consultation was related to patients reporting more tension (<i>P</i> = 0.002) and more decisional uncertainty (<i>P</i> = 0.004) at 1 wk after the consultation. The SDM element \"informing about the options\" was especially found to be related to adverse outcomes, specifically to more helplessness/hopelessness (<i>P</i> = 0.002) and more tension (<i>P</i> = 0.016) at 1 wk after the consultation. Whether the patient consulted an oncologist who had received SDM training or not was not significantly related to adverse outcomes. No relations with long-term adverse outcomes were found.</p><p><strong>Conclusions: </strong>It is important for oncologists to realize that for some patients, SDM may temporarily be associated with negative emotions. Further research is needed to untangle which, when, and how adverse outcomes might occur and whether and how burden may be minimized for patients.</p><p><strong>Highlights: </strong>Observed shared decision making was related to more tension and uncertainty postconsultation in advanced cancer patientsHowever, training oncologists in SDM did not affect adverse outcomes.Further research is needed to untangle which, when, and how adverse outcomes might occur and how burden may be minimized.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"89-101"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10712204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89720275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of a Decision Aid for Hip and Knee Osteoarthritis in Orthopedics: A Mixed-Methods Process Evaluation. 骨科髋关节和膝关节骨性关节炎决策辅助的实施:混合方法过程评估。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-01-01 Epub Date: 2023-10-30 DOI: 10.1177/0272989X231205858
Jeroen Klaas Jacobus Bossen, Julia Aline Wesselink, Ide Christiaan Heyligers, Jesse Jansen

Background: In orthopedics, the use of patient decision aids (ptDAs) is limited. With a mixed-method process evaluation, we investigated patient factors associated with accepting versus declining the use of the ptDA, patients' reasons for declining the ptDA, and clinicians' perceived barriers and facilitators for its use.

Methods: Patients with an indication for joint replacement surgery (N = 153) completed questionnaires measuring demographics, physical functioning, quality of life (EQ-5D-3L), and a visual analog scale (VAS) pain score at 1 time point. Subsequently, their clinician offered them the relevant ptDA. Using a retrospective design, we compared patients who used the ptDA (59%) with patients who declined (41%) on all these measures as well as the chosen treatment. If the use of the ptDA was declined, patients' reasons were recorded by their clinician and analysed (n = 46). To evaluate the experiences of clinicians (n = 5), semistructured interviews were conducted and thematically analyzed. Clinicians who did not use the ptDA substantially (<10 times) were also interviewed (n = 3).

Results: Compared with patients who used the ptDA, patients who declined use had higher VAS pain scores (7.2 v. 6.2, P < .001), reported significantly worse quality of life (on 4 of 6 EQ-5D-3L subscales), and were less likely to receive nonsurgical treatment (4% v. 28%, P < .001). Of the patients who declined to use the ptDA, 46% said they had enough information and felt ready to make a decision without the ptDA. The interviews revealed that clinicians considered the ptDAs most useful for newly diagnosed patients who had not received previous treatment.

Conclusion: These results suggest that the uptake of a ptDA may be improved if it is introduced in the early disease stages of hip and knee osteoarthritis.

Highlights: Patients who declined the use of a patient decision aid (ptDA) for hip and knee osteoarthritis reported more pain and worse quality of life.Most patients who declined to use a ptDA felt sufficiently well informed to make a treatment decision.Patients who declined the ptDA were more likely to have received prior treatment in primary care.Clinicians found the ptDA to be a helpful addition to the consultation, particularly for newly diagnosed patients.

背景:在骨科,患者决策辅助工具(ptDA)的使用是有限的。通过混合方法-过程评估,我们调查了与接受和拒绝使用ptDA相关的患者因素,患者拒绝使用ptDA的原因,以及临床医生对其使用的障碍和促进因素。方法:有关节置换手术适应症的患者(N = 153)在1个时间点完成了测量人口统计、身体功能、生活质量(EQ-5D-3L)和视觉模拟量表(VAS)疼痛评分的问卷调查。随后,他们的临床医生为他们提供了相关的ptDA。使用回顾性设计,我们比较了使用ptDA的患者(59%)和在所有这些指标以及所选治疗方面下降的患者(41%)。如果ptDA的使用减少,则由临床医生记录患者的原因并进行分析(n = 46)。评估临床医生的经验(n = 5) ,进行了半结构化访谈,并进行了主题分析。没有大量使用ptDA的临床医生(n = 3) 结果:与使用ptDA的患者相比,拒绝使用ptDA患者的VAS疼痛评分更高(7.2 vs.6.2,P P 结论:这些结果表明,如果在髋关节和膝关节骨关节炎的早期疾病阶段引入ptDA,可能会提高ptDA的摄取。亮点:拒绝使用患者决策辅助工具(ptDA)治疗髋关节和膝关节骨关节炎的患者报告称疼痛加剧,生活质量下降。大多数拒绝使用ptDA的患者都觉得自己有足够的信息来做出治疗决定。拒绝ptDA的患者更有可能在初级保健中接受过治疗。临床医生发现ptDA是对会诊的有益补充,尤其是对新诊断的患者。
{"title":"Implementation of a Decision Aid for Hip and Knee Osteoarthritis in Orthopedics: A Mixed-Methods Process Evaluation.","authors":"Jeroen Klaas Jacobus Bossen, Julia Aline Wesselink, Ide Christiaan Heyligers, Jesse Jansen","doi":"10.1177/0272989X231205858","DOIUrl":"10.1177/0272989X231205858","url":null,"abstract":"<p><strong>Background: </strong>In orthopedics, the use of patient decision aids (ptDAs) is limited. With a mixed-method process evaluation, we investigated patient factors associated with accepting versus declining the use of the ptDA, patients' reasons for declining the ptDA, and clinicians' perceived barriers and facilitators for its use.</p><p><strong>Methods: </strong>Patients with an indication for joint replacement surgery (<i>N</i> = 153) completed questionnaires measuring demographics, physical functioning, quality of life (EQ-5D-3L), and a visual analog scale (VAS) pain score at 1 time point. Subsequently, their clinician offered them the relevant ptDA. Using a retrospective design, we compared patients who used the ptDA (59%) with patients who declined (41%) on all these measures as well as the chosen treatment. If the use of the ptDA was declined, patients' reasons were recorded by their clinician and analysed (<i>n</i> = 46). To evaluate the experiences of clinicians (<i>n</i> = 5), semistructured interviews were conducted and thematically analyzed. Clinicians who did not use the ptDA substantially (<10 times) were also interviewed (<i>n</i> = 3).</p><p><strong>Results: </strong>Compared with patients who used the ptDA, patients who declined use had higher VAS pain scores (7.2 v. 6.2, <i>P</i> < .001), reported significantly worse quality of life (on 4 of 6 EQ-5D-3L subscales), and were less likely to receive nonsurgical treatment (4% v. 28%, <i>P</i> < .001). Of the patients who declined to use the ptDA, 46% said they had enough information and felt ready to make a decision without the ptDA. The interviews revealed that clinicians considered the ptDAs most useful for newly diagnosed patients who had not received previous treatment.</p><p><strong>Conclusion: </strong>These results suggest that the uptake of a ptDA may be improved if it is introduced in the early disease stages of hip and knee osteoarthritis.</p><p><strong>Highlights: </strong>Patients who declined the use of a patient decision aid (ptDA) for hip and knee osteoarthritis reported more pain and worse quality of life.Most patients who declined to use a ptDA felt sufficiently well informed to make a treatment decision.Patients who declined the ptDA were more likely to have received prior treatment in primary care.Clinicians found the ptDA to be a helpful addition to the consultation, particularly for newly diagnosed patients.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"112-122"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10714711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Mitigation and Control Policies in Realistic Epidemic Models Accounting for Household Transmission Dynamics. 考虑家庭传播动态的现实流行病模型中缓解和控制政策的效果。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-01-01 Epub Date: 2023-11-13 DOI: 10.1177/0272989X231205565
Fernando Alarid-Escudero, Jason R Andrews, Jeremy D Goldhaber-Fiebert
<p><strong>Background: </strong>Compartmental infectious disease (ID) models are often used to evaluate nonpharmaceutical interventions (NPIs) and vaccines. Such models rarely separate within-household and community transmission, potentially introducing biases in situations in which multiple transmission routes exist. We formulated an approach that incorporates household structure into ID models, extending the work of House and Keeling.</p><p><strong>Design: </strong>We developed a multicompartment susceptible-exposed-infectious-recovered-susceptible-vaccinated (MC-SEIRSV) modeling framework, allowing nonexponentially distributed duration in exposed and infectious compartments, that tracks within-household and community transmission. We simulated epidemics that varied by community and household transmission rates, waning immunity rate, household size (3 or 5 members), and numbers of exposed and infectious compartments (1-3 each). We calibrated otherwise identical models without household structure to the early phase of each parameter combination's epidemic curve. We compared each model pair in terms of epidemic forecasts and predicted NPI and vaccine impacts on the timing and magnitude of the epidemic peak and its total size. Meta-analytic regressions characterized the relationship between household structure inclusion and the size and direction of biases.</p><p><strong>Results: </strong>Otherwise similar models with and without household structure produced equivalent early epidemic curves. However, forecasts from models without household structure were biased. Without intervention, they were upward biased on peak size and total epidemic size, with biases also depending on the number of exposed and infectious compartments. Model-estimated NPI effects of a 60% reduction in community contacts on peak time and size were systematically overestimated without household structure. Biases were smaller with a 20% reduction NPI. Because vaccination affected both community and household transmission, their biases were smaller.</p><p><strong>Conclusions: </strong>ID models without household structure can produce biased outcomes in settings in which within-household and community transmission differ.</p><p><strong>Highlights: </strong>Infectious disease models rarely separate household transmission from community transmission. The pace of household transmission may differ from community transmission, depends on household size, and can accelerate epidemic growth.Many infectious disease models assume exponential duration distributions for infected states. However, the duration of most infections is not exponentially distributed, and distributional choice alters modeled epidemic dynamics and intervention effectiveness.We propose a mathematical framework for household and community transmission that allows for nonexponential duration times and a suite of interventions and quantified the effect of accounting for household transmission by varying household size and
背景:室状传染病(ID)模型常用于评估非药物干预措施(npi)和疫苗。这种模型很少将家庭和社区内部的传播分开,在存在多种传播途径的情况下可能会引入偏见。我们制定了一种将家庭结构纳入ID模型的方法,扩展了House和Keeling的工作。设计:我们开发了一个多隔室易感-暴露-感染-恢复-易感-接种(MC-SEIRSV)模型框架,允许暴露和感染隔室的非指数分布持续时间,跟踪家庭和社区内的传播。我们模拟的流行病随社区和家庭传播率、免疫力下降率、家庭规模(3或5人)以及暴露和感染隔间数量(每个1-3个)而变化。我们将没有家庭结构的其他相同模型校准到每个参数组合的流行曲线的早期阶段。我们比较了各模型对疫情的预测结果,并预测了NPI和疫苗对疫情高峰时间和规模及其总规模的影响。元分析回归表征了家庭结构包容性与偏差的大小和方向之间的关系。结果:在其他相似的模型中,有和没有家庭结构的模型产生了相同的早期流行曲线。然而,不考虑家庭结构的模型的预测是有偏差的。在没有干预的情况下,它们在峰值大小和总流行大小上向上偏倚,偏差还取决于暴露和感染隔间的数量。在没有家庭结构的情况下,模型估计的社区接触在高峰时间和规模上减少60%的NPI效应被系统地高估了。NPI降低20%,偏倚较小。由于疫苗接种对社区和家庭传播都有影响,因此他们的偏差较小。结论:在家庭内部和社区传播不同的情况下,没有家庭结构的ID模型可能产生有偏差的结果。传染病模型很少将家庭传播与社区传播分开。家庭传播的速度可能不同于社区传播,取决于家庭规模,并可能加速流行病的增长。许多传染病模型假定感染状态的持续时间呈指数分布。然而,大多数感染的持续时间不是指数分布的,分布选择改变了模拟的流行病动态和干预效果。我们提出了一个家庭和社区传播的数学框架,该框架允许非指数持续时间和一套干预措施,并通过改变家庭规模和感染状态的持续时间分布来量化计算家庭传播对模型流行病动力学的影响。如果不把家庭结构包括在内,就会对流行病的整个过程建模产生偏差,并导致在社区环境中采取不同的干预措施所产生的影响。在家庭规模较大的人群中以及传染性持续时间呈非指数分布的疾病中,流行动态更快、更强烈。建模者应考虑明确纳入家庭结构,以量化非药物干预措施(例如,就地避难)的影响。
{"title":"Effects of Mitigation and Control Policies in Realistic Epidemic Models Accounting for Household Transmission Dynamics.","authors":"Fernando Alarid-Escudero, Jason R Andrews, Jeremy D Goldhaber-Fiebert","doi":"10.1177/0272989X231205565","DOIUrl":"10.1177/0272989X231205565","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Compartmental infectious disease (ID) models are often used to evaluate nonpharmaceutical interventions (NPIs) and vaccines. Such models rarely separate within-household and community transmission, potentially introducing biases in situations in which multiple transmission routes exist. We formulated an approach that incorporates household structure into ID models, extending the work of House and Keeling.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;We developed a multicompartment susceptible-exposed-infectious-recovered-susceptible-vaccinated (MC-SEIRSV) modeling framework, allowing nonexponentially distributed duration in exposed and infectious compartments, that tracks within-household and community transmission. We simulated epidemics that varied by community and household transmission rates, waning immunity rate, household size (3 or 5 members), and numbers of exposed and infectious compartments (1-3 each). We calibrated otherwise identical models without household structure to the early phase of each parameter combination's epidemic curve. We compared each model pair in terms of epidemic forecasts and predicted NPI and vaccine impacts on the timing and magnitude of the epidemic peak and its total size. Meta-analytic regressions characterized the relationship between household structure inclusion and the size and direction of biases.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Otherwise similar models with and without household structure produced equivalent early epidemic curves. However, forecasts from models without household structure were biased. Without intervention, they were upward biased on peak size and total epidemic size, with biases also depending on the number of exposed and infectious compartments. Model-estimated NPI effects of a 60% reduction in community contacts on peak time and size were systematically overestimated without household structure. Biases were smaller with a 20% reduction NPI. Because vaccination affected both community and household transmission, their biases were smaller.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;ID models without household structure can produce biased outcomes in settings in which within-household and community transmission differ.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;Infectious disease models rarely separate household transmission from community transmission. The pace of household transmission may differ from community transmission, depends on household size, and can accelerate epidemic growth.Many infectious disease models assume exponential duration distributions for infected states. However, the duration of most infections is not exponentially distributed, and distributional choice alters modeled epidemic dynamics and intervention effectiveness.We propose a mathematical framework for household and community transmission that allows for nonexponential duration times and a suite of interventions and quantified the effect of accounting for household transmission by varying household size and","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"5-17"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89720274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating Risk Prediction with Data Collection Costs: Novel Estimation of Test Tradeoff Curves. 用数据收集成本评估风险预测:测试权衡曲线的新估计。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-01-01 Epub Date: 2023-11-22 DOI: 10.1177/0272989X231208673
Stuart G Baker

Background: The test tradeoff curve helps investigators decide if collecting data for risk prediction is worthwhile when risk prediction is used for treatment decisions. At a given benefit-cost ratio (the number of false-positive predictions one would trade for a true positive prediction) or risk threshold (the probability of developing disease at indifference between treatment and no treatment), the test tradeoff is the minimum number of data collections per true positive to yield a positive maximum expected utility of risk prediction. For example, a test tradeoff of 3,000 invasive tests per true-positive prediction of cancer may suggest that risk prediction is not worthwhile. A test tradeoff curve plots test tradeoff versus benefit-cost ratio or risk threshold. The test tradeoff curve evaluates risk prediction at the optimal risk score cutpoint for treatment, which is the cutpoint of the risk score (the estimated risk of developing disease) that maximizes the expected utility of risk prediction when the receiver-operating characteristic (ROC) curve is concave.

Methods: Previous methods for estimating the test tradeoff required grouping risk scores. Using individual risk scores, the new method estimates a concave ROC curve by constructing a concave envelope of ROC points, taking a slope-based moving average, minimizing a sum of squared errors, and connecting successive ROC points with line segments.

Results: The estimated concave ROC curve yields an estimated test tradeoff curve. Analyses of 2 synthetic data sets illustrate the method.

Conclusion: Estimating the test tradeoff curve based on individual risk scores is straightforward to implement and more appealing than previous estimation methods that required grouping risk scores.

Highlights: The test tradeoff curve helps investigators decide if collecting data for risk prediction is worthwhile when risk prediction is used for treatment decisions.At a given benefit-cost ratio or risk threshold, the test tradeoff is the minimum number of data collections per true positive to yield a positive maximum expected utility of risk prediction.Unlike previous estimation methods that grouped risk scores, the method uses individual risk scores to estimate a concave ROC curve, which yields an estimated test tradeoff curve.

背景:当风险预测用于治疗决策时,测试权衡曲线有助于研究者决定收集数据进行风险预测是否值得。在给定的收益-成本比(人们将假阳性预测的数量交换为真阳性预测)或风险阈值(在治疗和不治疗之间无差异的情况下发生疾病的概率)下,测试权衡是每个真阳性的最小数据收集数量,以产生正的最大预期风险预测效用。例如,每对癌症的真阳性预测进行3000次侵入性测试的权衡,可能表明风险预测是不值得的。测试权衡曲线绘制了测试权衡与收益成本比或风险阈值的关系。测试权衡曲线评估治疗的最佳风险评分切点处的风险预测,当接受者-工作特征(ROC)曲线为凹时,风险评分(发展疾病的估计风险)的切点使风险预测的预期效用最大化。方法:以前估计测试权衡的方法需要分组风险评分。利用个体风险评分,新方法通过构建ROC点的凹包络,取基于斜率的移动平均值,最小化平方误差和将连续的ROC点与线段连接起来,来估计凹的ROC曲线。结果:估计的凹ROC曲线产生估计的测试权衡曲线。对两个合成数据集的分析说明了该方法。结论:基于个体风险得分估算测试权衡曲线是直接实现的,并且比以前需要分组风险得分的估算方法更具吸引力。重点:当风险预测用于治疗决策时,测试权衡曲线有助于研究人员确定收集风险预测数据是否值得。在给定的收益成本比或风险阈值下,测试权衡是每个真正数据收集的最小数量,以产生正的最大预期风险预测效用。与以往的风险评分分组估计方法不同,该方法使用个体风险评分来估计凹的ROC曲线,从而产生估计的测试权衡曲线。
{"title":"Evaluating Risk Prediction with Data Collection Costs: Novel Estimation of Test Tradeoff Curves.","authors":"Stuart G Baker","doi":"10.1177/0272989X231208673","DOIUrl":"10.1177/0272989X231208673","url":null,"abstract":"<p><strong>Background: </strong>The test tradeoff curve helps investigators decide if collecting data for risk prediction is worthwhile when risk prediction is used for treatment decisions. At a given benefit-cost ratio (the number of false-positive predictions one would trade for a true positive prediction) or risk threshold (the probability of developing disease at indifference between treatment and no treatment), the test tradeoff is the minimum number of data collections per true positive to yield a positive maximum expected utility of risk prediction. For example, a test tradeoff of 3,000 invasive tests per true-positive prediction of cancer may suggest that risk prediction is not worthwhile. A test tradeoff curve plots test tradeoff versus benefit-cost ratio or risk threshold. The test tradeoff curve evaluates risk prediction at the optimal risk score cutpoint for treatment, which is the cutpoint of the risk score (the estimated risk of developing disease) that maximizes the expected utility of risk prediction when the receiver-operating characteristic (ROC) curve is concave.</p><p><strong>Methods: </strong>Previous methods for estimating the test tradeoff required grouping risk scores. Using individual risk scores, the new method estimates a concave ROC curve by constructing a concave envelope of ROC points, taking a slope-based moving average, minimizing a sum of squared errors, and connecting successive ROC points with line segments.</p><p><strong>Results: </strong>The estimated concave ROC curve yields an estimated test tradeoff curve. Analyses of 2 synthetic data sets illustrate the method.</p><p><strong>Conclusion: </strong>Estimating the test tradeoff curve based on individual risk scores is straightforward to implement and more appealing than previous estimation methods that required grouping risk scores.</p><p><strong>Highlights: </strong>The test tradeoff curve helps investigators decide if collecting data for risk prediction is worthwhile when risk prediction is used for treatment decisions.At a given benefit-cost ratio or risk threshold, the test tradeoff is the minimum number of data collections per true positive to yield a positive maximum expected utility of risk prediction.Unlike previous estimation methods that grouped risk scores, the method uses individual risk scores to estimate a concave ROC curve, which yields an estimated test tradeoff curve.</p>","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"53-63"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138292267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the Value of Provider-Facing Digital Health Technologies Used in Chronic Disease Management: Toward a Value Framework Based on Multistakeholder Perceptions. 评估面向提供者的数字健康技术在慢性病管理中的价值:基于多利益相关者感知的价值框架。
IF 3.1 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-01-01 Epub Date: 2023-10-26 DOI: 10.1177/0272989X231206803
Caitlin Main, Madeleine Haig, Danitza Chavez, Panos Kanavos
<p><strong>Objectives: </strong>Hardly any value frameworks exist that are focused on provider-facing digital health technologies (DHTs) for managing chronic disease with diverse stakeholder participation in their creation. Our study aimed to 1) understanding different stakeholder opinions on where value lies in provider-facing technologies and 2) create a comprehensive value assessment framework for DHT assessment.</p><p><strong>Methods: </strong>Mixed-methods comprising both primary and secondary evidence were used. A scoping review enabled a greater understanding of the evidence base and generated the initial indicators. Thirty-four indicators were proposed within 6 value domains: health inequalities (3), data rights and governance (6), technical and security characteristics (6), clinical characteristics (7), economic characteristics (9), and user preferences (3). Subsequently, a 3-round Web-Delphi was conducted to rate the indicators' importance in the context of technology assessment and determine whether there was consensus.</p><p><strong>Results: </strong>The framework was adapted to 45 indicators based on participant contributions in round 1 and delivered 16 stable indicators with consensus after rounds 2 and 3. Twenty-nine indicators showed instability and/or dissensus, particularly the data rights domain, in which all 5 indicators were unstable, showcasing the novelty of the concept of data rights. Significant instability between <i>important</i> and <i>very important</i> ratings was present within stakeholder groups, particularly clinicians and policy experts, indicating they were unsure how different aspects should be valued.</p><p><strong>Conclusions: </strong>Our study provides a comprehensive value assessment framework for assessing provider-facing DHTs incorporating diverse stakeholder perspectives. Instability for specific indicators was expected due to the novelty of data and analytics integration in health technologies and their assessment. Further work is needed to ensure that, across all types of stakeholders, there is a clear understanding of the potential impacts of provider-facing DHTs.</p><p><strong>Highlights: </strong>Current health technology assessment (HTA) methods may not be well suited for evaluating digital health technologies (DHTs) because of their complexity and wide-ranging impact on the health system.This article adds to the literature by exploring a wide range of stakeholder opinions on the value of provider-facing DHTs, creating a holistic value framework for these technologies, and highlighting areas in which further discussions are needed to align stakeholders on DHTs' value attributes.A Web-based Delphi co-creation approach was used involving key stakeholders from throughout the digital health space to generate a widely applicable value framework for assessing provider-facing DHTs. The stakeholders include patients, health care professionals, supply-side actors, decision makers, and academia from the Uni
目标:几乎没有任何价值框架专注于面向提供者的数字健康技术(DHT),以管理慢性病,并让不同的利益相关者参与其创建。我们的研究旨在1)了解不同利益相关者对面向提供商的技术价值所在的看法,2)为DHT评估创建一个全面的价值评估框架。方法:采用包括主要证据和次要证据的混合方法。范围审查使人们能够更好地了解证据基础,并产生初步指标。在6个价值领域内提出了34个指标:健康不平等(3)、数据权利和治理(6)、技术和安全特征(6),临床特征(7)、经济特征(9)和用户偏好(3)。随后,进行了三轮网络德尔菲,对指标在技术评估中的重要性进行评分,并确定是否达成共识。结果:该框架在第一轮中根据参与者的贡献调整了45个指标,并在第二轮和第三轮之后达成了16个稳定的指标。29项指标显示不稳定和/或不一致,特别是数据权领域,其中所有5项指标都不稳定,显示了数据权概念的新颖性。利益相关者群体,特别是临床医生和政策专家,在重要评级和非常重要评级之间存在显著的不稳定性,这表明他们不确定应该如何评估不同方面。结论:我们的研究为评估面向提供者的DHT提供了一个全面的价值评估框架,结合了不同的利益相关者的观点。由于卫生技术及其评估中数据和分析集成的新颖性,预计特定指标不稳定。需要进一步的工作,以确保所有类型的利益相关者都清楚地了解面向提供者的数字健康技术的潜在影响。亮点:当前的健康技术评估(HTA)方法可能不太适合评估数字健康技术,因为其复杂性和对卫生系统的广泛影响。这篇文章通过探索利益相关者对面向提供商的DHT价值的广泛意见,为这些技术创建一个整体的价值框架,并强调需要进一步讨论的领域,以使利益相关者在DHT的价值属性上保持一致,从而补充了文献。使用了一种基于网络的Delphi共创方法,涉及整个数字健康领域的关键利益相关者,以生成一个广泛适用的价值框架,用于评估面向提供者的DHT。利益相关者包括来自美国、英国和德国的患者、医疗保健专业人员、供应方参与者、决策者和学术界。利益相关者和价值领域之间存在高度不稳定,这表明评估提供者面临的DHT及其对卫生系统的影响是新颖的。
{"title":"Assessing the Value of Provider-Facing Digital Health Technologies Used in Chronic Disease Management: Toward a Value Framework Based on Multistakeholder Perceptions.","authors":"Caitlin Main, Madeleine Haig, Danitza Chavez, Panos Kanavos","doi":"10.1177/0272989X231206803","DOIUrl":"10.1177/0272989X231206803","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;Hardly any value frameworks exist that are focused on provider-facing digital health technologies (DHTs) for managing chronic disease with diverse stakeholder participation in their creation. Our study aimed to 1) understanding different stakeholder opinions on where value lies in provider-facing technologies and 2) create a comprehensive value assessment framework for DHT assessment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Mixed-methods comprising both primary and secondary evidence were used. A scoping review enabled a greater understanding of the evidence base and generated the initial indicators. Thirty-four indicators were proposed within 6 value domains: health inequalities (3), data rights and governance (6), technical and security characteristics (6), clinical characteristics (7), economic characteristics (9), and user preferences (3). Subsequently, a 3-round Web-Delphi was conducted to rate the indicators' importance in the context of technology assessment and determine whether there was consensus.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The framework was adapted to 45 indicators based on participant contributions in round 1 and delivered 16 stable indicators with consensus after rounds 2 and 3. Twenty-nine indicators showed instability and/or dissensus, particularly the data rights domain, in which all 5 indicators were unstable, showcasing the novelty of the concept of data rights. Significant instability between &lt;i&gt;important&lt;/i&gt; and &lt;i&gt;very important&lt;/i&gt; ratings was present within stakeholder groups, particularly clinicians and policy experts, indicating they were unsure how different aspects should be valued.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Our study provides a comprehensive value assessment framework for assessing provider-facing DHTs incorporating diverse stakeholder perspectives. Instability for specific indicators was expected due to the novelty of data and analytics integration in health technologies and their assessment. Further work is needed to ensure that, across all types of stakeholders, there is a clear understanding of the potential impacts of provider-facing DHTs.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;Current health technology assessment (HTA) methods may not be well suited for evaluating digital health technologies (DHTs) because of their complexity and wide-ranging impact on the health system.This article adds to the literature by exploring a wide range of stakeholder opinions on the value of provider-facing DHTs, creating a holistic value framework for these technologies, and highlighting areas in which further discussions are needed to align stakeholders on DHTs' value attributes.A Web-based Delphi co-creation approach was used involving key stakeholders from throughout the digital health space to generate a widely applicable value framework for assessing provider-facing DHTs. The stakeholders include patients, health care professionals, supply-side actors, decision makers, and academia from the Uni","PeriodicalId":49839,"journal":{"name":"Medical Decision Making","volume":" ","pages":"28-41"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10714693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50163436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medical Decision Making
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1